# The dynamics of mutational selection in cutaneous squamous carcinogenesis

**Authors:** Greta Skrupskelyte, Joanna C. Fowler, Stefan Dentro, Carine Winkler, Irina Abnizova, Niklas Beumer, Roshan Sood, Thomas Quarrell, Charlotte King, Jivko Kamarashev, Emmanuella Guenova, Moritz Gerstung, Benjamin A. Hall, Liliane Michalik, Philip H. Jones

PMC · DOI: 10.1038/s42003-025-09406-9 · 2026-01-12

## TL;DR

This study examines how mutations are selected during skin cancer development in mice, finding that only p53 mutants are consistently selected throughout the process.

## Contribution

The study introduces a method to analyze mutational selection in normal tissue alongside tumors, revealing dynamic selection patterns in carcinogenesis.

## Key findings

- Nonsynonymous Trp53 mutants were positively selected in both epidermis and tumors and present in 90% of tumors.
- Ten mutant genes were under negative selection in normal skin, with one also negatively selected in tumors.
- Other positively selected mutant genes lost their advantage in heavily mutated epidermis and tumors.

## Abstract

Identifying the mutant genes that are selected during carcinogenesis is key to identifying candidates for intervention and understanding the processes that promote transformation. Here we applied two selection metrics to study the dynamics of mutational selection in a mouse model of ultraviolet light driven skin carcinogenesis in which multiple synchronous tumors develop in each animal. Sequencing normal skin and tumors over a time course revealed two genetic routes to squamous carcinoma. Nonsynonymous Trp53 mutants were positively selected in both epidermis and tumors and present in 90% of tumors. The remaining tumors carried other oncogenic mutants, including activating Kras mutations. However, other positively selected mutant genes lost their competitive advantage in heavily mutated epidermis and in tumors. We found ten mutant genes under negative selection in normal skin, one of which was also negatively selected in tumors. In addition one gene was negatively selected in tumors but not normal skin. We conclude that analysing selection in normal tissue alongside tumors may resolve the dynamics of selection in carcinogenesis and refine the identification of cancer drivers.

Sequencing mutants in both normal skin and tumors that arise from it in a mouse model of ultraviolet light driven carcinogenesis reveals mutant selection changes as cancers develop. Only p53 mutants are selected throughout squamous carcinogenesis.

## Linked entities

- **Genes:** TP53 (tumor protein p53) [NCBI Gene 7157], KRAS (KRAS proto-oncogene, GTPase) [NCBI Gene 3845]
- **Diseases:** squamous carcinoma (MONDO:0005096)
- **Species:** Mus musculus (taxon 10090)

## Full-text entities

- **Genes:** SPINK5 (serine peptidase inhibitor Kazal type 5) [NCBI Gene 11005] {aka LEKTI, LETKI, NETS, NS, VAKTI}, SMO (smoothened, frizzled class receptor) [NCBI Gene 6608] {aka CRJS, FZD11, Gx, PHLS, SMOH}, AJUBA (ajuba LIM protein) [NCBI Gene 84962] {aka JUB}, FAT1 (FAT atypical cadherin 1) [NCBI Gene 2195] {aka CDHF7, CDHR8, FAT, ME5, hFat1}, ATP2A2 (ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 2) [NCBI Gene 488] {aka ATP2B, DAR, DD, RHABDO2, SERCA2}, SMARCA4 (SWI/SNF related BAF chromatin remodeling complex subunit ATPase 4) [NCBI Gene 6597] {aka BAF190, BAF190A, BRG1, CSS4, MRD16, OTSC12}, MTOR (mechanistic target of rapamycin kinase) [NCBI Gene 2475] {aka FRAP, FRAP1, FRAP2, RAFT1, RAPT1, SKS}, KMT2D (lysine methyltransferase 2D) [NCBI Gene 8085] {aka AAD10, ALR, BCAHH, CAGL114, KABUK1, KMS}, KMT2C (lysine methyltransferase 2C) [NCBI Gene 58508] {aka HALR, KLEFS2, MLL3}, KRAS (KRAS proto-oncogene, GTPase) [NCBI Gene 3845] {aka 'C-K-RAS, C-K-RAS, CFC2, K-RAS2A, K-RAS2B, K-RAS4A}, NOTCH2 (notch receptor 2) [NCBI Gene 4853] {aka AGS2, HJCYS, hN2}, TP53 (tumor protein p53) [NCBI Gene 7157] {aka BCC7, BMFS5, LFS1, P53, TRP53}, Fat1 (FAT atypical cadherin 1) [NCBI Gene 14107] {aka 2310038E12Rik, Fath, mFat1}, Trp53 (transformation related protein 53) [NCBI Gene 22059] {aka Tp53, bbl, bfy, bhy, p44, p53}, EGFR (epidermal growth factor receptor) [NCBI Gene 1956] {aka ERBB, ERBB1, ERRP, HER1, NISBD2, NNCIS}, Kras (Kras proto-oncogene, GTPase) [NCBI Gene 16653] {aka K-Ras, K-Ras 2, K-ras, Ki-ras, Kras-2, Kras2}, EP300 (EP300 lysine acetyltransferase) [NCBI Gene 2033] {aka KAT3B, MKHK2, RSTS2, p300}, RB1 (RB transcriptional corepressor 1) [NCBI Gene 5925] {aka OSRC, PPP1R130, RB, p105-Rb, p110-RB1, pRb}, ERBB2 (erb-b2 receptor tyrosine kinase 2) [NCBI Gene 2064] {aka CD340, HER-2, HER-2/neu, HER2, MLN 19, MLN-19}, TGFBR1 (transforming growth factor beta receptor 1) [NCBI Gene 7046] {aka AAT5, ACVRLK4, ALK-5, ALK5, ESS1, LDS1}, PIK3CA (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) [NCBI Gene 5290] {aka CCM4, CLAPO, CLOVE, CWS5, HMH, MCAP}, FAT2 (FAT atypical cadherin 2) [NCBI Gene 2196] {aka CDHF8, CDHR9, HFAT2, MEGF1, SCA45}, NOTCH1 (notch receptor 1) [NCBI Gene 4851] {aka AOS5, AOVD1, TAN1, hN1}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, Notch1 (notch 1) [NCBI Gene 18128] {aka 9930111A19Rik, Mis6, N1, Tan1, lin-12}, ROS1 (ROS proto-oncogene 1, receptor tyrosine kinase) [NCBI Gene 6098] {aka MCF3, ROS, c-ros-1}, Tgfbr1 (transforming growth factor, beta receptor I) [NCBI Gene 21812] {aka ALK5, Alk-5, ESK2, TGFR-1, TbetaR-I, TbetaRI}, Krt14 (keratin 14) [NCBI Gene 16664] {aka CK-14, K14, Krt-1.14, Krt1-14}, ERBB3 (erb-b2 receptor tyrosine kinase 3) [NCBI Gene 2065] {aka ErbB-3, FERLK, HER3, LCCS2, MDA-BF-1, VSCN1}, CASP8 (caspase 8) [NCBI Gene 841] {aka ALPS2B, CAP4, Casp-8, FLICE, MACH, MCH5}, Fat4 (FAT atypical cadherin 4) [NCBI Gene 329628] {aka 6030410K14Rik, 9430004M15}
- **Diseases:** metastasis (MESH:D009362), squamous cancer (MESH:D018307), weight loss (MESH:D015431), skin (MESH:D012871), SCC grade III (MESH:D001254), Darier's disease (MESH:D007644), carcinogenesis (MESH:D063646), AK (MESH:D055623), skin cancer (MESH:D012878), erythema (MESH:D004890), cSCC (MESH:D018366), cutaneous squamous cell carcinoma (MESH:D002294), SBS (MESH:D012640), Tumors (MESH:D009369), toxicity (MESH:D064420)
- **Chemicals:** EDTA (MESH:D004492), Tween-20 (MESH:D011136), Triton X-100 (MESH:D017830), paraformaldehyde (MESH:C003043), eosin (MESH:D004801), hematoxylin (MESH:D006416), CO2 (MESH:D002245), paraffin (MESH:D010232), PBS (MESH:D007854), saponin (MESH:D012503), Alexa Fluor 555 (MESH:C000608607), OCT (MESH:C051883), ERP166414 (-)
- **Species:** Mus musculus (house mouse, species) [taxon 10090], Homo sapiens (human, species) [taxon 9606]
- **Cell lines:** SKH-1 — Homo sapiens (Human), Chronic myelogenous leukemia, BCR-ABL1 positive, Cancer cell line (CVCL_C124)

## Figures

7 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12855962/full.md

---
Source: https://tomesphere.com/paper/PMC12855962